Patents by Inventor Scott V. Monte

Scott V. Monte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and system to provide personalized pharmaceutical compositions and dosages
    Patent number: 9443060
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: September 13, 2016
    Assignee: VOLANT HOLDINGS GMBH
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Method and System to Provide Personalized Pharmaceutical Compositions and Dosages
    Publication number: 20150235002
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio.
    Type: Application
    Filed: April 2, 2015
    Publication date: August 20, 2015
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Method and system to provide personalized pharmaceutical compositions and dosages
    Patent number: 8999721
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: April 7, 2015
    Assignee: Therabrake, Inc.
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Method and System to Provide Personalized Pharmaceutical Compositions and Dosages
    Publication number: 20140037739
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio.
    Type: Application
    Filed: January 30, 2013
    Publication date: February 6, 2014
    Applicant: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Method and system to provide personalized pharmaceutical compositions and dosages
    Patent number: 8367418
    Abstract: The invention provides a method for determining a suitable drug combination for the treatment of Type 2 diabetes by obtaining data from a Type 2 diabetes population in which all of the Type 2 diabetics are not taking any Type-2 diabetes drugs and obtaining reference levels of glucose supply and insulin demand parameters. Data from discrete samples of Type 2 diabetes populations in which all individuals are being treated with one or more Type 2 diabetes drugs at a therapeutic dose are also obtained, and the effects of the drugs on the glucose supply and insulin demand parameters are used to determine adjustment factors which represent the effect of each of the drugs at the therapeutic dosage, which are used to determined a ratio of a Glucose Supply Index (S) to an Insulin Demand Index (D). The ratio is further utilized in scoring cardiovascular risks for Type 2 diabetics and recommending therapeutic interventions.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: February 5, 2013
    Assignee: TheraSyn Sensors, Inc.
    Inventors: Scott V. Monte, Frank Bright, Jerome Schentag
  • METHOD AND SYSTEM TO PROVIDE PERSONALIZED PHARMACEUTICAL COMPOSITIONS AND DOSAGES
    Publication number: 20110097807
    Abstract: The invention provides a method for determining a suitable drug combination for the treatment of Type 2 diabetes by obtaining data from a Type 2 diabetes population in which all of the Type 2 diabetics are not taking any Type-2 diabetes drugs and obtaining reference levels of glucose supply and insulin demand parameters. Data from discrete samples of Type 2 diabetes populations in which all individuals are being treated with one or more Type 2 diabetes drugs at a therapeutic dose are also obtained, and the effects of the drugs on the glucose supply and insulin demand parameters are used to determine adjustment factors which represent the effect of each of the drugs at the therapeutic dosage, which are used to determined a ratio of a Glucose Supply Index (S) to an Insulin Demand Index (D). The ratio is further utilized in scoring cardiovascular risks for Type 2 diabetics and recommending therapeutic interventions.
    Type: Application
    Filed: October 25, 2010
    Publication date: April 28, 2011
    Inventors: Scott V. Monte, Frank Bright, Jerome Schentag